Bernhard J. Woermann

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Christian Buske, Eva Hoster, Martin Dreyling et al. · Leukemia · 2008 · 155 citations

Medicine, Oncology, Immuno-oncology Pharmacotherapy +5

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Philipp A. Greif, Annika Dufour, Nikola P. Konstandin et al. · Blood · 2012 · 147 citations

Life Sciences, Genetics, Molecular Genetics +16

Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia

Friederike Pastore, Annika Dufour, Tobias Benthaus et al. · Journal of Clinical Oncology · 2014 · 113 citations · Full text

Medicine, Oncology, Cytogenetics +14

Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis

Matthias Stelljes, Utz Krug, Dietrich W. Beelen et al. · Journal of Clinical Oncology · 2013 · 107 citations · Full text

Medicine, Oncology, Chemotherapy +12

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Tobias Herold, Klaus H. Metzeler, Sebastian Vosberg et al. · Blood · 2014 · 105 citations

Life Sciences, Genetics, Molecular Genetics +15